Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Thursday, April 6, 2017 Genetics & Stem Cells News
Email Print This Page Comment
Font : A-A+

NEW YORK, April 5, 2017 /PRNewswire/ -- Pipeline OverviewT-cell immunotherapy mainly consists of T-cell receptor (TCR), Tumor-infiltrating

lymphocytes (TILs) and Chimeric antigen receptors (CAR) T-cell therapy. TCR is a complex integral membrane protein that activates T-cells in response to an antigen. Major histocompatibility complex (MHC) molecules activates TCR by the presence of an
antigen. The activation of TCR initiates positive and negative cascades that leads to cellular proliferation, cytokine production, cellular differentiation, and/or activation of induced cell death. These signaling positive and negative cascades regulate T-cell development, homeostasis, activation, acquisition of effector's functions and apoptosis.Read the full report: http://www.reportlinker.com/p04713812/Global-T-Cell-Immunotherapy-Pipeline-Analysis-Clinical-Trials-Results-Patent-Designation-Collaboration-and-Other-Developments.htmlTILs, defined by NCI, the U.S. federal government's principal agency for cancer research and training, as a preparation of cells consisting of autologous tumor infiltrating lymphocytes, that are manipulated in vitro and, upon administration in vivo, re-infiltrate the tumor to initiate tumor cell lysis. In vitro, TILs are isolated from tumor tissue and cultured with lymphokines such as interleukin-2. The therapeutic TILs are then infused into patients, where after re-infiltration of the tumor, they may induce lysis of tumor cells and tumor regression. The use of therapeutic TILs is considered as an adoptive immunotherapy.The high prevalence of cancer and increased safety and efficacy across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer as it has several advantages over conventional therapies such as very low or no side effects and high specificity.T Cell Immunotherapy Pipeline AnalysisPipeline AnalysisThe T-cell immunotherapy pipeline is very strong with a total of 139 drug candidates. Pharma giant such as Novartis, Kite Pharmaceuticals, Juno Therapeutics, Inc. and Sorrent Therapeutics, Inc. are actively involved in development of these therapeutics. There are 16 drug candidates in Phase II stage of development, 36 in Phase I, and seven in Phase 0. Two drug candidates have been filed for Investigational New Drug (IND) application, and there are 78 drugs in Pre-clinical and Discovery stage.NY-ESO-1 is under Phase II stage of development by Kite Pharmaceuticals Inc. for the treatment of solid tumors including, but not limited to sarcoma, bladder cancer, esophageal carcinoma, non-small cell lung cancer, breast carcinoma, ovarian carcinoma, prostate carcinoma, multiple myeloma, hepatocellular carcinoma and melanoma. The therapeutic candidate targets NY-ESO-1 antigen and being produced by using Engineered Autologous Cell Therapy (eACT) technology. In addition, CART-EGFR, also known as Anti-EFGR-CAR vector-transduced T-cells, is under Phase I/II stage of development by Cellular Biomedicine Group Inc. for the treatment of advanced EGFR-positive solid tumors.Competitive LandscapeSeveral companies are involved in T-cell immunotherapy, with their products in different phases. Sorrento Therapeutics, Inc. is developing 21 products based on CAR T-cell therapy. The company is using CAR.TNK technology platform and G-MAB fully human antibody technology for the development of its therapeutic candidates. Novartis Pharmaceuticals has nine products in their pipeline and one drug candidate reached into Phase II clinical stage. Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc., Juno Therapeutics, Inc., Gradalis, Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics Plc., Immunocore Limited, and Lion Biotechnologies, Inc.Scope for CustomizationP&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of developmentRead the full report: http://www.reportlinker.com/p04713812/Global-T-Cell-Immunotherapy-Pipeline-Analysis-Clinical-Trials-Results-Patent-Designation-Collaboration-and-Other-Developments.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-t-cell-immunotherapy-pipeline-analysis-2016---clinical-trials--results-patent-designation-collaboration-and-other-developments-300435445.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook